AUTL - Company ID 0001730463
The table below shows Autolus Therapeutics plc's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $26.22M | $21.19M | $20.92M | $8.98M | $0.00 | $0.00 |
| Cost of revenue | $24.57M | $28.64M | $24.45M | $17.95M | $0.00 | $0.00 |
| Gross profit | - | - | - | - | - | - |
| R&D | $21.21M | $27.89M | $27.43M | $26.73M | $40.32M | $36.61M |
Autolus Therapeutics plc reported annual revenue of $75.39M for fiscal year 2025. That is up 644.9% from $10.12M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $1.21M (FY 2016) to $75.39M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $39.95M |
| $36.28M |
| $30.27M |
| $29.54M |
| $27.33M |
| $21.90M |
| Operating income | -$59.51M | -$71.62M | -$61.22M | -$65.24M | -$67.88M | -$58.93M |
| Income tax | $863.00K | $532.00K | $397.00K | $2.23M | $22.00K | $51.00K |
| Net income | -$71.60M | -$79.12M | -$47.92M | -$70.16M | -$82.09M | -$58.27M |
| EPS (diluted) | -$0.27 | -$0.30 | -$0.18 | -$0.26 | -$0.31 | -$0.22 |